Robby Nieuwlaat
Education
Nieuwlaat obtained a Master of Science in Health Sciences in 2001, and PhD in cardiovascular clinical epidemiology in 2007 from Maastricht University in the Netherlands.
Career and Affiliations
Population Health Research Institute (2008-2011)
Nieuwlatt worked as a post-doctoral research fellow at the Population Health Research Institute in Hamilton from 2008 until 2011.1)
McMaster University (2011-present)
Nieuwlaat is an Associate Professor in the Department of Health Research Methods, Evidence, and Impact at McMaster University.2) He was hired at the school in 2011.
He is a researcher in the MacGRADE Centre of McMaster University, and a researcher at the Michael G. DeGroote Cochrane Canada Centre.3)
Radcliffe Cardiology
Nieuwlaat is an author with Radcliffe Cardiology.4)
Cochrane Heart
Nieuwlaat is a Cochrane Heart editorial board member.5)
GRADE Working Group
Nieuwlaat is a member of the GRADE Working Group.6)
OMERACT
Nieuwlaat is a member of the OMERACT-Adherence group, studying outcomes in rheumatology. He has co-authored publications funded by a 2018 Arthritis Australia project grant (major funder), and a private research grant provided by Professor Stephen Hall.7)
Canadian Stroke Prevention Intervention Network
Nieuwlaat is a Principal Investigator for the Knowledge Translation Program at the Canadian Stroke Prevention Intervention Network.8)
INGUIDE
Nieuwlaat is a member of the Program Steering Committee for the International Guideline Development Credentialing Certification Program (INGUIDE).9)
Research
Funding
Nieuwlaat has published research funded by the American Society of Hematology (ASH),10) the Canadian Institutes of Health Research (CIHR), Global Alliance for Chronic Disease, Ontario SPOR Support Unity, Ontario Ministry of Health and Long-Term Care, and the World Health Organization.11)
Further funding to study arterial fibrillation has come from AstraZeneca, the Australian Heart Foundation, Austrian Society of Cardiology, Eucomed, French Federation of Cardiology, Hellenic Cardiological Society, Netherlands Heart Foundation, Portuguese Society of Cardiology, Spanish Cardiac Society, the Swedish Heart and Lung Foundation, and Sanofi.12)
He is a member of the Global Alliance for Chronic Diseases (GACD) Hypertension Research Programme, funded by the Canadian Institutes of Health Research (CIHR), Grand Challenges Canada, International Development Research Centre, Canadian Partnership for Stroke Recovery, Australian National Health and Research Council, National Institutes of Health, National Heart, Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, United Kingdom Medical Research Council, and the South African Medical Research Council.13)
Yet further research has been funded by AstraZeneca, Sanofi, Boehringer Ingelheim, Eucomed, University of Basel, and Marche Polytechnic University.14) 15) 16)
COVID-19
Nieuwlaat was lead author on a paper discussing antimicrobial resistance and COVID-19 sponsored by the World Health Organization.17)
2)
Nieuwlaat, Robby. (2022). McMaster University Faculty of Health Sciences. https://archive.ph/MZHzx
3)
Robby Nieuwlaat. McMaster Experts. Retrieved June 11, 2022, from https://archive.ph/yPEhO
5)
Editors. (2022). Cochrane Heart. https://archive.ph/JbE5a
6)
Piggott, T., Baldeh, T., Dietl, B., Wiercoch, W., Nieuwlaat, R., Santesso, N., Coello, P. A., & Schünemann, H. J. (2022). Standardized wording to improve efficiency and clarity of GRADE EtD frameworks in health guidelines. Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2022.01.004
7)
Kelly, A., Tong, A., Tymms, K., March, L., Craig, J. C., De Vera, M., Evans, V., Hassett, G., Toupin-April, K., van den Bemt, B., Teixeira-Pinto, A., Alten, R., Bartlett, S. J., Campbell, W., Dawson, T., Gill, M., Hebing, R., Meara, A., Nieuwlaat, R., & Shaw, Y. (2018). Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 19(1). https://doi.org/10.1186/s13063-018-2565-z
8)
Robby Nieuwlaat. (2014). Canadian Stroke Prevention Intervention Network. https://archive.ph/YcMI6
9)
About. International Guideline Credentialing & Certification Program. Retrieved June 9, 2022, from https://archive.ph/XmtCe
10)
Mustafa, R. A., Garcia, C. A. C., Bhatt, M., Riva, J. J., Vesely, S., Wiercioch, W., Nieuwlaat, R., Patel, P., Hanson, S., Newall, F., Wiernikowski, J., Monagle, P., & Schünemann, H. J. (2021). GRADE notes: How to use GRADE when there is “no” evidence? A case study of the expert evidence approach. Journal of Clinical Epidemiology, 137, 231–235. https://doi.org/10.1016/j.jclinepi.2021.02.026
11)
Khan, M., Lamelas, P., Musa, H., Paty, J., McCready, T., Nieuwlaat, R., Ng, E., Lopez-Jaramillo, P., Lopez-Lopez, J., Yusoff, K., Majid, F. A., Ng, K. K., Garis, L., Onuma, O., Yusuf, S., & Schwalm, J.-D. (2018). Development, testing, and implementation of a training curriculum for nonphysician health workers to reduce cardiovascular disease. Global Heart, 13(2), 93-100.e1. https://doi.org/10.1016/j.gheart.2017.11.002
12)
Dudink, E. A. M. P., Erküner, Ö., Berg, J., Nieuwlaat, R., de Vos, C. B., Weijs, B., Capucci, A., Camm, A. J., Breithardt, G., Le Heuzey, J.-Y., Luermans, J. G. L. M., & Crijns, H. J. G. M. (2017). The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. EP Europace, 20(6), 929–934. https://doi.org/10.1093/europace/eux217
13)
Riddell, M. A., Edwards, N., Thompson, S. R., Bernabe-Ortiz, A., Praveen, D., Johnson, C., Kengne, A. P., Liu, P., McCready, T., Ng, E., Nieuwlaat, R., Ovbiagele, B., Owolabi, M., Peiris, D., Thrift, A. G., Tobe, S., & Yusoff, K. (2017). Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program. Globalization and Health, 13(1). https://doi.org/10.1186/s12992-017-0242-8
14)
Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205
15)
Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review. Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011
16)
Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793
17)
Nieuwlaat, R., Mbuagbaw, L., Mertz, D., Burrows, L., Bowdish, D. M. E., Moja, L., Wright, G. D., & Schünemann, H. J. (2020). COVID-19 and antimicrobial resistance: parallel and interacting health emergencies. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa773